The COX-2 inhibitor market has gotten heated up with launched of generics and new drugs
Pfizer has made movements to prevent the ‘Sales Cliff’ phenomenon in which sales decline after the patent expiration of the selective COX-2 inhibitor ‘Celebrex (generic name: celecoxib)’ that will be expired in June this year.
Followed by the expiration, several top domestic pharmaceutical compa...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
